Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

BACKGROUND: HER-2 represents a relatively new therapeutic target for non small cell lung cancer (NSCLC) patients. The incidence for reported HER-2 overexpression/amplification/mutations ranges from 2 to 20% in NSCLC. Moreover, HER-2 amplification is a potential mechanism of resistance to tyrosine ki...

Descripción completa

Detalles Bibliográficos
Autores principales: Cretella, Daniele, Saccani, Francesca, Quaini, Federico, Frati, Caterina, Lagrasta, Costanza, Bonelli, Mara, Caffarra, Cristina, Cavazzoni, Andrea, Fumarola, Claudia, Galetti, Maricla, La Monica, Silvia, Ampollini, Luca, Tiseo, Marcello, Ardizzoni, Andrea, Petronini, Pier Giorgio, Alfieri, Roberta R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058446/
https://www.ncbi.nlm.nih.gov/pubmed/24898067
http://dx.doi.org/10.1186/1476-4598-13-143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058446/
https://www.ncbi.nlm.nih.gov/pubmed/24898067
http://dx.doi.org/10.1186/1476-4598-13-143

Ejemplares similares